News

Ms Ellen joins GlaxoSmithKline (GSK) from Pfizer where she was vice president, licensing, worldwide business development. During her career, Ms Ellen has worked in a variety of roles

Martin Welschof, CEO of Affitech, said: “I thank Oyvin Broymer, who took over the chairmanship of Affitech in 2002 at a time of major strategic change and has

Following feedback from regulatory authorities, the company plans to conduct an additional Phase III clinical trial with dalbavancin for the treatment of adults with complicated skin and skin

The contract is the third that National Institute of Allergy and Infectious Diseases has awarded to Xoma for the development of botulinum antitoxins and brings the program’s total

The five-year agreement provides Celling with an initial two year period of exclusive distribution rights in the US and non-exclusive distribution rights throughout the rest of the world,

AlignRT for the HiArt platform is said to consist of two ceiling-mounted 3D camera units, each focused toward the external isocenter of the radiotherapy device. Immediately prior to

Zeno Corporation’s board of directors has approved the name change during the August 2008 board meeting. The first FDA-approved device of its kind, Zeno has influenced the over-the-counter

The Phase I/II trial is a randomized, double-blind, vehicle-controlled and parallel-assigned study evaluating the effects of OMS302 on dilation of the pupil during cataract surgery and on pain,

These are said to be MiCardia’s first Dynaplasty technology products to receive clearance. MiCardia is developing the Dynaplasty technology for the percutaneous and non-invasive treatment of structural heart